Lambert to speak at C5 Pharma & Biotech Patent Litigation Conference on 28 Feb 2017
Jane Lambert One of the most important cases of 2017 was the Supreme Court's decision in Eli Lilly v Actavis UK Ltd and Others [2017] Bus LR 1731, [2017] UKSC 48. That case is important for two reasons. First, it re-struck the balance that the law has to strike between the needs of inventors for reasonable protection for their inventions, competitors in the industry for certainty and clarity as to what they can and cannot do and the general the general public for reasonable competition much more favourably to inventors. Secondly, the Court considered for the first time topics such as the "doctrine of equivalents" and "file wrapper estoppel" that are familiar to US judges and lawyers but not to their colleagues in this country. I wrote about that case in The Supreme Court's Judgment in Eli Lilly v Actavis UK Ltd and Others: how to understand it and why it is important 13 July 2017 NIPC Law. My case note received a lot of hits and favourab